资讯

Should You Buy, Sell or Hold AstraZeneca Stock Before Q1 Earnings?
AZN's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, are expected to have driven the company's top line.
Ozempic for a sharper brain? Weight loss drugs can cut dementia risk by a staggering 45%
Two new studies published in JAMA Neurology reveal that GLP-1 receptor agonists, like Ozempic and Trulicity, may significantly reduce the risk of dementia, particularly in individuals with type 2 ...
pharmaphorum6 年
AZ backs diabetes drug Farxiga with new cardio analysis
AstraZeneca continues to make the case for its Farxiga diabetes drug, highlighting a cardiology analysis that it hopes will convince more doctors to prescribe it in a highly competitive market.
Medical Marketing & Media8 天
Trump sides with pharma, pledges support for change to IRA’s ‘pill penalty’
The Trump administration made a decidedly pro-industry statement on the Inflation Reduction Act (IRA). In an executive order issued Tuesday, President Donald Trump outlined changes to the Biden ...
pharmaphorum6 年
Study shows AZ's Farxiga diabetes drug cuts heart risks
AstraZeneca’s Farxiga has become the latest type 2 diabetes drug to show it can reduce cardiovascular risk in a clinical trial. Boehringer Ingelheim and Eli Lilly’s Jardiance (empagliflozin ...
Drugs like Ozempic could ‘significantly’ cut Alzheimer’s risk, study finds
New research suggests that GLP-1 drugs like Ozempic and Wegovy, commonly used for diabetes and weight loss, may also reduce the risk of Alzheimer's disease and dementia.